Agency: European Commission | Branch: H2020 | Program: IA | Phase: ICT-28-2015 | Award Amount: 15.72M | Year: 2016
Bringing flexible organic electronics to pilot innovation scale (PI-SCALE) is a highly needed response to bridge the gap which exists today between promising laboratory scale results of highly efficient flexible OLED modules and mass manufacturing of high value-added products. The project will integrate existing European infrastructures into a European flexible OLED pilot line, which will operate in an open access mode and serve customers from along the value chain with individual product designs, validation of upscaling concepts, and system-level flexible OLED integration. The Consortium will connect the most advanced pilot line facilities with the best material providers and equipment manufacturers, creating a service that will offer substantial numbers of flexible OLEDs that can meet efficiency, durability and cost requirements of end users. Together with end-users for various markets, such as automotive and designer luminaires, PI-SCALE will demonstrate the capabilities of this pilot line doing process optimisation for product demonstrators to enable cost efficient production and facilitate an effective market introduction. In addition PI-SCALE will include a number of outreach activities to actively engage and educate interested users and suppliers for flexible OLEDs in interactive product concept development. PI-SCALE will not only support the market acceptance of flexible OLED products, but it will also ensure that prototype ideas from European companies will have the possibility of reaching a semi-industrial scale in a very short time.
Agency: European Commission | Branch: H2020 | Program: IA | Phase: PILOTS-01-2016 | Award Amount: 8.10M | Year: 2017
The project targets the incorporation of advanced functional materials to deliver customised conductive inks and flexible adhesives compatible with high volume manufacturing platforms. Specifically the development of these enabling materials will support high speed roll to roll integration of hybrid and large area electronics to address internet of things opportunities. The consortium will integrate materials development with end application requirements in terms of technical performance (thermal/electrical conductivity, processing conditions, materials integrity and adhesion) and unit cost of production to facilitate market adoption. The project will utilise and build on existing CPI pilot facilities (R2R print line) to demonstrate technology integration, manufacturability and produce components for end user evaluation to enable the direct comparison of production techniques. The project delivers a supply chain to support future commercialisation: incorporating materials suppliers of inks and adhesives, supporting RTO in Formulation and nano-particle production, established high fidelity print equipment manufacturers, electronic device manufacturers, established pilot line facilities and potential end users from the apparel, packaging and healthcare sector relating to the internet of things.
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: ICT-29-2016 | Award Amount: 1.40M | Year: 2017
EPRISE project aims to promote and support Photonics as a KET with focus on Life Science applications in 4 target markets where Europe holds a leading position Medical Technologies, Pharmaceuticals, Agriculture and Food. Companies developing photonics-based products for these markets face highly specific Go-to-Market challenges such as long time to market adoption, complex regulatory frameworks and high barriers to market entry to name but a few. They are often in need of support from public funding to help them cross the Valley of death between innovation ready phase (TRL 4), and investment ready phase (TRL 7). During this time, they are also in need of advice from market specific experts who can guide them on non-technological (business) topics. EPRISE consortium will organise a European Photonics Roadshow, a series of 7 major events hosted by European regions, with the aim of providing SMEs with concrete solutions from market experts on how to overcome market barriers and boosting collaboration along the complete value chain via pre-arranged B2B meetings. Photonics clusters involved in EPRISE have both local connections and technology understanding to set-up, together with Regional Authorities, an efficient framework that will encourage creation of funding synergies between regional and European funds in order to better exploit potential of European Photonics industry. The project aims to provide regional policy makers with an overview of funding synergies to be considered in the current or following Multiannual Financial Framework (MFF). Furthermore, the project aims to establish a formal collaboration with the ongoing European Photonics projects offering technology support (ActPhast, Pix4Life) that can address potential technology issues linked to SMEs access to market.
Agency: European Commission | Branch: H2020 | Program: IA | Phase: ICT-02-2016 | Award Amount: 9.08M | Year: 2017
The InSCOPE project will set-up an open access pilot line service for Hybrid TOLAE (H-TOLAE) technologies capable of sampling products at TRL6-7. It positions itself in between R&D and industry and deploys a service for validating potential H-TOLAE products. Manufacturing progresses beyond R&D level (TRL5 towards 6) by improving processes, functionality and reliability allowing sampling at high quality and in relevant numbers needed for industrial qualification (TRL 6-7). The applications addressed cover automotive, healthcare, smart packaging and buildings. After InSCOPE, the Pilot line service will remain accessible to interested parties. The pilot line is serviced by top European RTDs with leading technological positions and state of the art equipment in the domain of H-TOLAE. InSCOPE will set up an open access pilot line infrastructure for H-TOLAE technology, which is modular ensuring a comprehensive toolbox of printing, assembly, production integration and process validation distributed over the partners. InSCOPE will ensure interoperability between the differing modules at the partners enabling end-users to combine different processes step from different partners in their process flow. It will accelerate the uptake of H-TOLAE technology by delivering a public handbook describing functionalities, production guidelines and design rules of H-TOLAE, including new opportunities for traditional electronics. Validation of the pilot line service by 4 Showcases and 15 development cases are included within the project. The Showcases consist of H-TOLAE product prototypes at TRL 5 to be matured on functionality and on manufacturability. The showcases will steer the pilot line improvement. They are selected based on their economic impact as well as the technological status of the product and production in Europe. The development cases are devoted to new functionalities enabled by H-TOLAE. They are aimed at SMEs interested in exploring the broad advantages H-TOLAE.
Agency: European Commission | Branch: H2020 | Program: CSA | Phase: NMBP-30-2016 | Award Amount: 626.12K | Year: 2016
AceForm4.0 will strengthen European leadership in the development and commercialisation of innovative and sustainable formulated products by i) engaging stakeholders and establishing a strategic common vision, European 2025 roadmap for formulated products and an associated implementation plan; and ii) facilitating knowledge exchange activities aiming at the formation of new collaborative value chains and partnerships in the context of the challenges, barriers and opportunities offered by Industry 4.0 and the drive towards a Circular Economy. Whilst a number of the challenges faced by manufacturers of formulated products are shared with the wider process industry, their nature is very different. Being often micro-heterogeneous, formulated products tend to be unstable and rely on a judicious selection of ingredients and fine-tuned production methods to guarantee physical and chemical stability during their lifetime. Compared to basic chemicals, this makes product development far more challenging in terms of, e.g.: 1) predicting the properties of combined ingredients at an early stage of their lifecycle for optimal use of ingredients; 2) designing new manufacturing processes and equipment; 3) selection of adequate modelling and simulation processes to minimise resources and energy utilisation; 4) scale-up from lab to production; and 5) developing in-stream high throughput metrology to enable quality control, plant automation and supply chain management. AceForm4.0 will establish and engage a European-wide Formulation Interest Group, comprising of stakeholders from industry, research institutes and government bodies to identify specific cross-sector challenges, barriers and opportunities. The resulting common European strategy will provide a framework for the rational development of sustainable products and stimulate targeted investment in RDI initiatives leading to new commercialised products, manufacturing facilities and services.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: FETOPEN-1-2014 | Award Amount: 3.53M | Year: 2016
Separation and purification of biopharmaceuticals is today one of the most time and cost intense Downstream Processing (DSP) operations in the manufacture of commercial products. Separation and purification of proteins is usually achieved chromatographically, with all of its disadvantages including high buffer requirements, large footprint, reuse and storage of resin studies as well as costs. Traditional DSP based on batch chromatography contribute ca. 66% of the total production cost of anti-cancer monoclonal antibodies (mAbs). Largely contributing to this is the cost of chromatography media; for instance, the cost of 1 L of protein A resin with binding capacity of 20-70 g mAb is about 25000 Eur. By a visionary and ambitious combination of the emerging Continuous Manufacturing Paradigm with innovative Membrane Crystallization Technology and the selective nanotemplate-recognitions directly from the fermentation broth, the AMECRYS Network aims to develop a new Continuous Template-Assisted Membrane Crystallizer in order to revolutionize the DSP platform for mAbs production, thus achieving unprecedented purification and manufacturing efficiencies. Major research challenges will include: i) the synthesis of 3D-nanotemplates with specific molecular recognition ability towards mAbs from complex solutions; ii) the development of tailored macroporous fluoropolymer membranes for advanced control of selective heterogeneous nucleation; iii) the design of multilevel microfluidic devices for high-throughput mAb crystallization screening in a wide range of conditions under continuous flow (pharma-on-a-chip concept); iv) technology scale-up to a L-scale continuous prototype designed with recognition of QS/GMP compliance for biopharmaceuticals. The replacement of chromatography with a single membrane-crystallization unit will lead to >60% CapEx and O&M costs decrease, 30-fold footprint reduction and high-purity solid formulation of mAbs with preserved biological activity.
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: NMP-08-2014 | Award Amount: 8.34M | Year: 2015
A number of nanomedicine formulations have enabled, or been shown to hold considerable potential for enabling more effective and less toxic therapeutic interventions. However, progress to date in translating these initiatives to commercial success has been limited. One of the main reasons for this bottleneck is due to the inability of researchers and stakeholders to manufacture batches of the nanomedicine product at the required scale and according to Good Manufacturing Practice (GMP) requirements. The NANOFACTURING project will focus on - facilitating access to required infrastructures and expertise - creating GMP pilot lines for up-scaling manufacturing - addressing the current developmental and production gaps - taking nanomaterials already successfully produced at proof-of-concept/milligram levels and facilitating their scale-up to sub-kilogram quantities - providing large-scale and GMP production for clinical trials and nanomedicine translation. The NANOFACTURING project, through a consortium of 9 partners, will develop the synthetic processes, process control methods, analytical assays for QA/QC, functional specifications, and best practices, interfacing existing R&D centres of excellence, transfer organisations and private GMP manufacturing facilities (including SMEs) to ensure efficient translation from discovery through to first in man, proof-of-concept studies and beyond to Phase III according to industrial and regulatory standards. Specifically, the NANOFACTURING project aims to create a platform process for early, mid- and large-scale manufacturing of glycan-coated gold nanoparticles (GNPs), a widely researched and developed class of self-forming nanoparticles. The ability to engineer new nanopharmaceuticals based on this patent protected platform technology, developed by Midatech Biogune S.L. (Project Coordinator), will have inherent advantages over existing treatments for multiple therapeutic areas.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 1.05M | Year: 2015
This project will develop a process which uses seaweed for the generation of sustainable energy by anaerobic digestion (AD). Currently, farmers, food processors and industry use AD to generate bio-methane from wastes, to reduce energy costs or provide income. As waste supplies can be variable and AD is a continuous process, food crops like maize and beets are used to supplement waste. Seaweed has the potential to replace these food crops, which use land and water which could otherwise be used for human food production. The UK has extensive coastal waters and internationally recognised academic excellence in seaweed, its growth requirements and environmental considerations. This project brings together expertise in AD process development, economic modelling, environmental and social impact assessment and the supply chain - from seabed access for seaweed farming through to biogas injection into the national grid.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Centre | Award Amount: 14.00M | Year: 2014
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 427.98K | Year: 2016
The project, ALGIPRO, is an innovative collaborative effort between Norway and the UK. It will translate over 20 years of academic research into an industrial scale production process for alginates. The Centre for Process Innovation Ltd. (UK) is leading the scale-up based on development by SINTEF (Norway). AlgiPharma AS (Norway) will use the product as the Active Pharmaceutical Ingredient in its development of medicines for cystic fibrosis, COPD and chronic wounds. FMC Biopolymer (UK, Norway) will market the product in existing and new applications within the food and pharmaceutical markets. If successful ALGIPRO will facilitate the introduction of novel medicinal products to the market that will ease patient suffering and potentially reduce healthcare costs. In addition it will be a new tool in fighting multi-drug resistant bacteria.